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Abstract
Introduction
Various prognostic models have been developed for acute stroke, including one based on
age and five binary variables (‘six simple variables’model; SSVMod) and one based on age
plus scores on the National Institutes of Health Stroke Scale (NIHSSMod). The aims of this
study were to externally validate and recalibrate these models, and to compare their predic-
tive ability in relation to both survival and independence.
Methods
Data from a large clinical trial of oxygen therapy (n = 8003) were used to determine the dis-
crimination and calibration of the models, using C-statistics, calibration plots, and Hosmer-
Lemeshow statistics. Methods of recalibration in the large and logistic recalibration were
used to update the models.
Results
For discrimination, both models functioned better for survival (C-statistics between .802 and
.837) than for independence (C-statistics between .725 and .735). Both models showed
slight shortcomings with regard to calibration, over-predicting survival and under-predicting
independence; the NIHSSMod performed slightly better than the SSVMod. For the most
part, there were only minor differences between ischaemic and haemorrhagic strokes.
Logistic recalibration successfully updated the models for a clinical trial population.
Conclusions
Both prognostic models performed well overall in a clinical trial population. The choice
between them is probably better based on clinical and practical considerations than on sta-
tistical considerations.
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Introduction
There is current interest in the development and testing of prognostic models in acute stroke.
Such models provide estimates of outcome for individual patients based on a number of pre-
dictors [1]. They may also be useful in audit and resource allocation at the service level. In
research, prognostic models may provide important epidemiological data, and may be used to
determine case-mix and/or subgrouping in intervention studies [2].
Prognostic models in stroke are characteristically based upon information on the individu-
al’s health and functional capacity at the time of–or immediately preceding–the stroke and
clinimetric measures indicating stroke severity [3,4]. A well-performing prognostic model
should exhibit discrimination, calibration, parsimony and practicality (see Box 1 for
definitions).
Teale et al [8] reviewed 17 externally validated prognostic models in acute stroke. Methodo-
logical weaknesses were identified in a number of these models, and some lacked appropriate
validation in independent samples. Two models that were found to perform well are the six
simple variables model (SSVMod) [9] and the NIHSS + age model (NIHSSMod) [10].
The prognostic models
The SSVMod was developed in data from the Oxford Community Stroke Project, a commu-
nity-based incidence study of first-ever stroke [9], and is based upon six variables: age, as a con-
tinuous variable, and five binary variables, coded yes/no (living alone; independent pre-stroke;
normal Glasgow Coma Scale verbal score [4]; able to lift both arms against gravity; able to walk
unaided). Patients on whom the SSVMod was developed were assessed at a median of 4 days
post stroke. Predictions can be derived for 30-day survival and for independence at 6 months.
The more recent NIHSSMod was developed from a database in the Stiftung Deutsche Schla-
ganfall-Hilfe, a data bank representing a hospital-based cohort [10], and is based on two vari-
ables: age and the National Institutes of Health Stroke Scale (NIHSS) [3], which provides a
single score for stroke severity based on 13 items. Patients were assessed on the NIHSS within 6
hours of the stroke. This model allows probabilities to be calculated for both death and depen-
dence (operationalized in the model as ‘incomplete recovery’) at 100 days post stroke. Table 1
gives details of the models.
Both these models have been individually validated in several studies [11–16]; see Table 2.
However, their relative performance has received little attention. A recent study [16] compared
Box 1. Desirable properties of prognostic models
Discrimination (accuracy of classification): The model should correctly classify individu-
als in terms of a positive (e.g. functional recovery) or negative (e.g. death) future state,
and thereby exhibit high levels of sensitivity and specificity [5].
Calibration (accurate estimates of risk): The model should correctly predict, for a
given risk, the proportion of patients who will achieve a specified future state. This is
achieved by determining how well the probabilities derived from the model agree with
observed outcomes [5].
Parsimony: The model should achieve good discrimination and calibration on the
basis of a manageable quantity of information derived from data likely to be available for
most, or preferably all, patients [6].
Practicality: The model should permit easy calculation of prognostic risk, especially if
used in routine clinical practice, and be easy to interpret [7].
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the NIHSSMod with the SSVMod and an adaptation of the SSVMod in which one variable (the
score for living alone) was omitted, in relation to independence at 3 and 12 months. The
NIHSSMod produced measures of calibration slightly superior to those of the SSVMod
(though not significantly). The models performed comparably in patients with haemorrhagic
versus ischaemic strokes [16]. No attempt to recalibrate the models (i.e. to adjust their coeffi-
cients) appears to have been made hitherto.
Aims
The current study therefore sought to evaluate further the discrimination and calibration of the
SSVMod and the NIHSSMod in a cohort of stroke patients from a randomized controlled trial.
Specific aims were to:
Table 1. Details of the original predictive models [9,11].
Model Coefﬁcients
Constant NIHSS Age Living
alone:
yes
Independent pre-
stroke: yes
Normal GCS
verbal score;
yes
Able to life both
arms against
gravity; yes
Able to walk
unaided; yes
SSVMod–survival* – ‡ – multiply by
0.034
– 0.406 + 0.501 + 0.766 + 0.851 + 0.489
SSVMod—
independence†
12.340 – multiply by
–0.051
+ 0.661 – 2.744 – 2.160 – 2.106 – 1.311
NIHSSMod—
mortality†
– 7.040 multiply by
0.155
multiply by
0.049
– – – – –
NIHSSMod—
independence†
– 5.782 multiply by
0.272
multiply by
0.049
– – – – –
* Cox survival model
† Logistic regression model
‡ Baseline survival at 30 days = 0.631
doi:10.1371/journal.pone.0153527.t001
Table 2. Characteristics of previous validation studies.
Study Population Type of stroke presentation Clinical presentation Model(s)
validated
Counsell
et al [11]
Trial patients (n = 2955). Mean age 73 years,
50% male
Any. 89% independent before stroke. SSVMod
Reid et al
[12]
Hospital-based stroke register (n = 538).
Median age 74 yrs, 53% male.
Hyperacute stroke (87%
ischaemic).
Median stroke severity 6 out of 10.*
81% independent before stroke.
SSVMod
König et al
[13]
Trial patients (n = 5419). Mean age 69, 59%
male.
Ischaemic. Mean NIHSS score 13.4. 44% with
Barthel Index (0–100 version)
score  95.
NIHSSMod
SCOPE [14] Trial patients (n = 537). Mean age 74 yrs,
54% male.
Hyperacute ischaemic stroke
(21% had had previous stroke).
97% independent before stroke. SSVMod
Teale et al
[15]
Hospital-based cohort study (n = 176). Mean
age 73, 53% male.
Transient ischaemic attack
excluded; otherwise
unspeciﬁed.
Median Barthel Index (0–20 version)
score 17
SSVMod
Ayis et al
[16]
Hospital-based (mainly) stroke registers
across countries (n = 2033). Mean age 71
years, 52% male.
First strokes only (82%
ischaemic).
Median stroke severity ‘moderate’. †
90% independent before stroke. ‡
SSVMod and
NIHSSMod
* High scores indicate greater severity
† Based on NIHSS score between 5 and 14
‡ Based on Barthel Index (0–20 version) score between 12 and 20.
doi:10.1371/journal.pone.0153527.t002
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• determine the external validity of the models by comparing their performance in an external
data set different from those of the original derivation studies.
• compare their performance in subgroups of patients with either ischaemic or haemorrhagic
strokes.
• compare the predictive ability of the models and their generalizability to timepoints other
than those on which they were developed.
• recalibrate the models in a clinical trial population.
Methods
Data
The models were validated in a cohort of patients from the Stroke Oxygen Study [17], a large
(n = 8003) randomized trial of oxygen therapy in hospitalized patients with acute stroke,
recruited in 136 collaborating centres in the UK between 2008 and 2013. The inclusion criteria
for the trial were that patients must have had a stroke within the preceding 24 hours and have
no definite indications for, or definite contraindications against, oxygen therapy. Exclusion cri-
teria were patients with other serious life-threatening conditions likely to lead to death within
the following few months (who would, therefore, be unlikely to benefit from oxygen treat-
ment), or patients in whom stroke was not the main clinical problem. Patients were treated in
the first 72 hours with either continuous oxygen, nocturnal oxygen, or no oxygen. We analysed
the 8003 patients who had reached at least the three-month outcome point–with no missing
values in respect of the predictor variables in the models–at the time of the present study. Sub-
groups of patients with either ischaemic (n = 6369) or haemorrhagic (n = 559) strokes were
identified (these do not comprise the total study sample, as the nature of 1075 patients’ stroke
was undetermined).
The outcomes of independence and incomplete recovery were defined in relation to a score
<3 on the Oxford Handicap Scale (OHS) [18] and a score>95 on the Barthel Index (0–100
version)[19], respectively–as per the original studies [9,10]. To make the models comparable,
probabilities for death and incomplete recovery were converted to those for survival and com-
plete recovery, respectively. The modified Rankin Scale (mRS) was used in the validation sam-
ple as a proxy for the OHS, as the relevant cutoffs are equivalent [18]. Follow-up data on the
mRS were collected by post, or by telephone in the case of non-responders.
Table 3 defines the outcomes against which the models were tested. The timepoints at
which outcomes were assessed differed in one respect from those for which the models were
Table 3. Characteristics of the prognostic models.
Outcome 1: survival Outcome 2: independence
SSVMod NIHSSMod SSVMod NIHSSMod
Probability given by model Survival Death* Independence Incomplete recovery†
Scale for outcome Binary Binary Oxford Handicap Scale (< 3)‡ Barthel index (< 95)
Time of prediction 30 days 100 days 6 months 100 days
Statistical method used Cox regression Logistic regression Logistic regression Logistic regression
* converted to survival for analysis
† converted to complete recovery for analysis
‡ equivalent point on the modiﬁed Rankin Scale was used in analysis
doi:10.1371/journal.pone.0153527.t003
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developed–the NIHSSMod was assessed at 100 days rather than 6 months. The data used for
the testing of the models is in S1 Data.
Validation methods
The prognostic characteristics of the models to be tested were discrimination (the ability of the
model to distinguish participants with the outcome from those without) and calibration (the
extent to which outcomes predicted by the model in specified risk-defined subgroups are similar
to those observed in the validation dataset) [5]. Statistical analysis was performed in Stata 13.
The discrimination of the models was assessed using the concordance (C) statistic; for binary
outcomes this is equivalent to the area under the receiver operating characteristic (ROC) curve
[20], which plots sensitivity against 1 minus specificity. The C-statistic normally ranges from .5
to 1, with a value of 1 representing perfect discrimination and a value of .5 representing discrimi-
nation no better than chance. C-statistics were determined in relation to the observed binary out-
comes (survived/died; independent/dependent) at the relevant timepoints. The difference
between the C-statistics estimated for the models was tested statistically for each outcome [21].
The calibration of the models was displayed using calibration plots, which plot the model
predictions against grouped observations in the data. For a well-calibrated model, the plotted
markers should lie on or near the diagonal reference line. Calibration in the large (mean cali-
bration) of the models was tested by comparing the observed and predicted outcomes of the
model in a logistic regression model, with the risk score as an offset variable; a non-significant
difference between predicted and observed outcomes indicates good calibration. Calibration
was further tested by using a Hosmer-Lemeshow (HL) goodness of fit statistic, which compares
observed and predicted outcomes in groups of patients. More than one method of grouping is
recommended [20], and the HL statistic was therefore calculated in relation to deciles of risk,
deciles of patient numbers, and the maximum number of groups (up to 100, with group
size 5). A non-significant HL test indicates good calibration. The magnitude of miscalibra-
tion was calculated as the calibration slope. This is the regression slope of the linear predictor,
and the closer the slope coefficient is to 1, the better the calibration [22]. A slope below 1 may
indicate unduly extreme predictions (i.e. low predictions were too low and high predictions
were too high) whereas a slope greater than 1 may indicate that predictions do not vary suffi-
ciently (i.e. predicted risks are too low)[23,24].
Model recalibration
The models were updated by a process of recalibration. First, the models were updated using
recalibration in the large, which adjusts the average predicted probability so that it equals the
observed event rate. This method can be applied when a difference in the outcome incidence is
suspected [25]. Second, the models were updated by logistic recalibration [26], which corrects
the mean calibration and adjusts the regression coefficients of the predictor by a single adjust-
ment factor. This method can be applied when the coefficients of the original model may have
been over-fitted; it assumes the relative effects of the predictors are similar but allows the pre-
dictors to have a larger or smaller effect. See Appendix for details of these methods.
Ethics
The Stroke Oxygen Study received approval from the North Staffordshire Research Ethics
Committee on 24th January 2007 (COREC 06/Q2604/109). Written informed consent was
obtained from all participants where possible. For patients not competent to give written con-
sent at the time of enrolment, assent was obtained from a relative or an independent physician
and full informed consent was obtained from the patient when he or she was competent to give
Prognostic Models in Acute Stroke
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it. These patients were not excluded from the trial as a considerable proportion of acute stroke
patients will have receptive and/or expressive problems and it was considered important for
the trial results to be generalizable to these patients. The Ethics Committee approved this con-
sent procedure.
Results
Demographic characteristics of the original and the validation samples are shown in Table 4.
The age of patients in the validation sample was similar to that of patients in the SSVMod
development sample, but somewhat higher than that of patients in the NIHSSMod develop-
ment sample. Sex distribution also differs, with a higher proportion of males in the validation
sample than in the SSVMod development sample but a smaller proportion than in the NIHSS-
Mod development sample. The median (interquartile range [IQR]) SSVMod risk scores for
independence and survival in the validation sample were .427 (.120, .712) and .921 (.859, .955),
respectively. The median (interquartile range) NIHSSMod risk scores in the validation sample
for incomplete recovery and death were .316 (.174, .603) and .071 (.040, .135), respectively.
Ninety-two percent of patients in the validation sample were independent prior to their stroke.
Twenty-six percent were able to walk unaided at the time of randomization.
Discrimination
Fig 1 shows the ROC curves for survival and independence for the SSVMod (plots a and c)
and the NIHSSMod (plots b and d), for the whole sample. Table 5 shows the corresponding C-
statistics and tests for difference for the total sample, and Table 6 shows the corresponding infor-
mation for the subgroups. Overall, C-statistics for survival exceed those for independence, indi-
cating better discrimination. In the subgroups, other than for 30-day survival, discrimination
appears slightly worse for haemorrhagic than for ischaemic strokes. For 6-month independence,
C-statistics from the NIHSSMod are larger than those from the SSVMod, except among haemor-
rhagic strokes, whereas for 3-month independence C-statistics from the SSVMod exceed those
from the NIHSSMod; the C-statistic for the NIHSSMod among haemorrhagic strokes is particu-
larly low at .684. Each model therefore discriminates somewhat better with respect to its ‘own’
outcome, though it should be noted that a number of the differences in C-statistics were non-sig-
nificant. Discrimination also tends to be better for earlier than for later outcomes.
Calibration
Calibration in the large for the two outcomes is shown for each model in Table 7. Both models
under-predicted the number of patients surviving at 30 and 100 days and over-predicted the
number independent at 3 (NIHSSMod) and 6 months (SSVMod); the p values from the logistic
regression test indicate that the discrepancy was not, however, significant in respect of
Table 4. Demographic characteristics of the original and validation samples.
Outcome 1: survival Outcome 2: independence
SSVMod NIHSSMod SSVMod NIHSSMod
Age in original sample, years; mean (SD) 73 (12) 67 (12) 73 (12) 67 (12)
Age in validation sample, years; mean (SD) 72 (13) 72 (13) 71 (13) 71 (13)
Sex in original sample; % male 48 61 48 61
Sex in validation sample; % male 55 55 56 57
Denominators for survival: 8003 for both models. Denominators for independence: 5667 for SSVMod, 5373 for NIHSSMod)
doi:10.1371/journal.pone.0153527.t004
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independence in relation to the SSVMod. The figures in Table 7 for ischaemic and haemorrha-
gic stroke are similar.
In relation to both survival and independence, the HL test was significant, for each method
of grouping, in relation to both the SSVMod and the NIHSSMod model (data not shown). The
calibration slope for survival was 1.308 for the SSVMod and 0.975 for the NIHSSMod. For
independence, the calibration slope was 0.470 for the SSVMod and 0.629 for the NIHSSMod.
The slopes are closer to 1 for survival than for independence, suggesting superior calibration.
Calibration plots are shown in Fig 2; as the methods of grouping produced similar results in
the HL test, plots are shown just for deciles of patient numbers. Judged by the approximation
of the plotted markers to the diagonal, the NIHSSMod (plots b and d) appears to show better
calibration than the SSVMod (plots a and c), for both outcomes.
Model recalibration
Table 8 shows the results for the recalibration of the two models, using both recalibration in
the large (updating the intercept) and logistic recalibration (updating the intercept and the
Fig 1. Receiver operating characteristics (ROC) curves for survival and independence, for the total sample.Optimally, the curve should lie towards
the upper left corner of the plot. Survival: assessed at 30 days for the SSVMod and at 100 days for the NIHSSMod. Independence: assessed at 6 months for
the SSVMod and at 3 months for the NIHSSMod.
doi:10.1371/journal.pone.0153527.g001
Prognostic Models in Acute Stroke
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slope; see Appendix). Logistic recalibration produced models with good calibration, confirmed
by a non-significant HL test. However, recalibration in the large only gave a non-significant
HL test for the NIHSSMod for 100-day survival.
Discussion
This study sought to perform a comparative validation of the SSVMod and the NIHSSMod by
examining their discrimination and calibration in an external dataset derived from a large ran-
domized trial; these characteristics of the models were also tested in subgroups of patients with
either ischaemic or haemorrhagic strokes. Additionally, the two models were updated in the
context of a clinical trial population.
In this study, discrimination was somewhat better for survival than for independence for
both models; however, higher discrimination may be anticipated for outcomes such as death
Table 5. C-statistics for survival and independence.
SSVMod NIHSSMod Test for equality
C-statistic 95% CI n C-statistic 95% CI n p value
30-day survival
total .816 .794, .838 8003 .837 .815, .858 8003 .001
100-day survival
total .802 .784, .820 8003 .823 .806, .840 8003 < .001
3-month-independence
total (1) — — — .728 .714, .741 5373 —
total (2) .735 .722, .748 5373 .728 .714, .741 5373 .160
6-month independence
total (1) .725 .712, .739 5667 — — — —
total (2) .725 .712, .739 5667 .731 .718, .745 5667 .242
(1) Estimate using all available data
(2) Estimate using pairwise deletion. CI = conﬁdence interval.
doi:10.1371/journal.pone.0153527.t005
Table 6. C-statistics for survival and independence in subgroups defined by type of stroke (ischaemic and haemorrhagic). The p values from the
tests for equality of the C-statistics should be interpreted with regard to the differing denominators of ischaemic and haemorrhagic strokes.
SSVMod NIHSSMod Test for equality
C-statistic 95% CI n C-statistic 95% CI n p value
30-day survival
ischaemic .815 .791, .840 6369 .834 .809, .858 6369 .008
haemorrhagic .809 .714, .904 559 .838 .749, .928 559 .109
100-day survival
ischaemic .805 .785, .825 6369 .823 .804, .843 6369 .002
haemorrhagic .788 .721, .855 559 .818 .751, .885 559 .066
6-month independence
ischaemic .730 .715, .745 4546 .737 .722, .752 4546 .252
haemorrhagic .722 .670, .774 398 .710 .657, .763 398 .523
3-month independence
ischaemic .741 .726, .756 4318 .735 .720, .750 4318 .310
haemorrhagic .712 .660, .765 373 .684 .630, .738 373 .148
CI = conﬁdence interval
doi:10.1371/journal.pone.0153527.t006
Prognostic Models in Acute Stroke
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that are measured without error and for which predictors are often easier to identify. Addition-
ally, discrimination tended to be better for earlier than for later outcomes, probably because
there is less likelihood of intervening events that may influence outcome. There are some dif-
ferences between ischaemic and haemorrhagic strokes. Haemorrhagic strokes are often fatal,
largely irrespective of the patient’s age. Patients with ischaemic strokes, even severe ones, are
more likely to die of complications than as a result of the stroke, and such complications may
be more likely in older patients. Both of these considerations suggest that prognostic models
incorporating age may perform better in ischaemic than in haemorrhage strokes. The NIHSS-
Mod shows noticeably lower discrimination than the SSVMod for haemorrhagic strokes in
relation to 3-month independence. However, p values for the mean calibrations and the com-
parisons between C-statistics must be interpreted with caution, owing to the different denomi-
nators in these comparisons.
Both the prognostic models showed shortcomings with regard to calibration, tending to
over-predict survival and under-predict independence. This may partly reflect the eligibility
criteria of the RCT sample–in which, for example, moribund patients were not included–and
improvements in care (e.g. due to thrombolysis and care in specialized stroke units) since the
models were first developed. Also relevant is that the development cohort for the NIHSSMod
[10] excluded patients with pre-existing disability (mRS score3), and the cohort for the
SSVMod [9] is likely to have excluded early deaths by virtue of collecting data for the model at
a median of 5 days after stroke, in contrast to within 24 hours of stroke onset in the validation
cohort. Accordingly, both models might be expected to give different predictions of survival
(and of independence in the case of the NIHSSMod) in our validation cohort. However, well-
calibrated models will fail a statistical test if the sample is large, owing to increased statistical
power. As was observed for discrimination, calibration, as judged by the calibration slopes, was
better for survival than for independence, and similar factors to those suggested in the case of
discrimination are likely to explain this. Reflecting the relative magnitudes of the calibration
slopes, the calibration plots indicate that the NIHSSMod performs slightly better than the
SSVMod. There is, however, little difference in the calibration of the models between ischaemic
and haemorrhagic strokes, reflecting earlier findings [16].
In comparison with other studies, the C-statistics calculated as a measure of discrimination
for 100-day survival were lower than those reported by Ayis et al [16] for 3-month survival (.80
Table 7. Calibration in the large of the models. Data are counts (%); p values are derived from a logistic regression model. Figures are given for all
patients and separately for those with ischaemic and haemorrhagic strokes.
SSVMod NIHSSMod
Observed Expected p value Observed Expected p value
Survival
total 7628 (95.3) 7068 (88.3) <0.001 7378 (92.2) 7000 (87.5) < .001
ischaemic 6066 (95.2) 5263 (82.6) <0.001 5867 (92.1) 5568 (87.4) < .001
haemorrhagic 531 (95.0) 494 (88.4) <0.001 511 (91.4) 489 (87.5) < .001
Independence
total 3422 (60.4) 2659 (46.9) 0.160 2685 (50.0) 2001 (37.2) < .001
ischaemic 2733 (60.1) 2137 (47.0) 0.098 2146 (49.7) 1607 (37.2) < .001
haemorrhagic 239 (60.1) 189 (47.5) 0.562 185 (49.6) 132 (35.4) < .001
Survival: assessed at 30 days for the SSVMod and at 100 days for the NIHSSMod. Independence: assessed at 6 months for the SSVMod and at 3
months for the NIHSSMod. Denominators for survival: 8003 for both models (6369 for ischaemic, 559 for haemorrhagic). Denominators for independence:
5667 for SSVMod (4546 for ischaemic, 398 for haemorrhagic); 5373 for NIHSSMod (4318 for ischaemic, 373 for haemorrhagic).
doi:10.1371/journal.pone.0153527.t007
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vs .90 for the SSVMod, .82 vs .88 for the NIHSSMod). This might appear to reflect the longer
prediction time in our study, except that the C-statistics for 30-day survival were also lower
than Ayis et al’s figures for 3-month survival. A more plausible explanation is that participants
Fig 2. Calibration plots for survival and independence, for the total sample and based on deciles of patient numbers. Survival: assessed at 30 days
for the SSVMod and at 100 days for the NIHSSMod. Independence: assessed at 6 months for the SSVMod and at 3 months for the NIHSSMod. For
illustrative clarity, the origins for the axes vary between plots.
doi:10.1371/journal.pone.0153527.g002
Table 8. Recalibration of the SSVMod and the NIHSSMod.
Model and outcome Recalibrated parameter estimates Hosmer-Lemeshow test (p values)
Recalibration in the
large
Logistic
recalibration
Original Recalibration in the
large
Logistic
recalibration
SSVMod: 30-day survival 0.813e(LP) 0.813e(1.308 x LP) < .001 < .001 .509
NIHSSMod: 100-day survival –0.655 + LP –0.688 + (0.975 x LP) < .001 .346 .307
SSVMod: 6-month independence 0.869 + LP 0.628 + (0.470 x LP) < .001 < .001 .239
NIHSSMod: 100-day
independence
0.735 + LP 0.425 + (0.629 x LP) < .001 < .001 .155
LP = original linear predictor equation (see also Table 1)
doi:10.1371/journal.pone.0153527.t008
Prognostic Models in Acute Stroke
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from a clinical trial are likely to be more homogeneous than patients in a community or general
clinical population, making discrimination more difficult. Furthermore, independence was
defined by Ayis et al as a score12 on the Barthel Index (0–20 version), rather than in terms
of the mRS, as in our validation study. In relation to the NIHSSMod, the C-statistic for 100-day
survival was higher in our study than in König et al’s study [13] (.82 vs .71) but that for
3-month independence as lower (.73 vs .81). This may reflect differences in the two cohorts–
König et al’s patients were somewhat younger than those in our cohort (69 vs 72), but with a
higher mean NIHSS score (13 vs 7). For the SSVMod, the C-statistic for 30-day survival was
higher than that reported by SCOPE [14] (.82 vs .73). In contrast, the C-statistic for 6-month
independence (.73) was lower than those reported by SCOPE (.82) [14] and Reid et al (.79)
[12]. The calibration plot for 30-day survival appears to be worse than that reported by SCOPE
[14], but the plots for 90-day independence are similar. Differences vis-à-vis the SCOPE study
may again reflect differences in the patient population–the SCOPE study included almost
exclusively patients who were independent before stroke. In addition, we used the mRS as a
proxy for the OHS, which was utilized in the SCOPE study. Whilst the meaning of the relevant
cutoff (<3) is equivalent in the two scales, the cutoff is described using somewhat different
wording [18], which may account for some of the difference in findings.
Although there is some indication that the NIHSSMod performs better than the SSVMod in
terms of calibration and, for survival, in terms of discrimination, differences between the mod-
els are generally small and the small p values reflect the large sample size; it is therefore hard to
reach a conclusive judgment regarding the relative predictive power of the two models. It is
likely that judgments as to the relative utility of the two models should instead be related to
clinical and practical considerations. The SSVMod requires information on a small number of
variables, whereas the NIHSS is a multi-item scale requiring a degree of training [27]–though
the NIHSS is becoming a standard method of clinical assessment in acute stroke and nomo-
grams and computer programs exist for both the SSVMod and the NIHSSMod. The NIHSS
scores a person’s current performance and has to be undertaken as part of a clinical examina-
tion. In contrast, the SSVMod is a combination of aspects of physical performance and the his-
tory readily collected from clinical records or by interview. Information for the SSVMod may
therefore be quicker and easier to collect. Notwithstanding this, in the UK, the NIHSS is col-
lected as a matter of standard practice as part of the Sentinel Stroke National Audit Programme
(SSNAP; https://www.rcplondon.ac.uk/projects/sentinel-stroke-national-audit-programme).
The NIHSSMod, unlike the SSVMod, does not reflect pre-stroke status; this may not be prob-
lematic in trial populations, as patients who are dependent pre-stroke are excluded in most tri-
als, but it may be less appropriate for everyday clinical populations, where pre-stroke
dependence may be a more important predictive factor.
It has been recommended that, rather than developing new models ab initio, researchers
should look at recalibrating existing models [1]. In our study, updating of the models in the
context of a clinical trial population using recalibration in the large was successful for the
NIHSSMod in respect of 100-day survival, but not for the other model/outcome combinations,
where the significant HL tests indicate inadequate calibration. In contrast, logistic recalibration
was successful for all model/outcome combinations. As recalibration in the large only updates
the average predicted risk, this was expected to be less effective than logistic recalibration. The
logistic recalibration thereby provided updated models suitable for a clinical trial population.
Extrapolation to clinical populations is less certain, given that they are commonly more hetero-
geneous than trial populations–nonetheless, the broad inclusion criteria and minimal exclusion
criteria for the trial, and the fact that the intervention tested within the trial is commonly used
in clinical practice in the UK [28], suggest that the recalibrated models are likely to have some
broader clinical relevance.
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Appendix
Details of the methods of model updating
Recalibration in the large. This method is used in cases where a difference in the outcome inci-
dence is suspected [26]. For the logistic regression models this was achieved by fitting a model
with only one free parameter, and with an offset variable equal to the linear predictor of the
original model. The models were updated by adding the coefficient of the free parameter to the
linear predictor; the individual risks were then recalculated:
recalibrated linear predictor ¼ updated interceptþ original linear predictor
For the survival analysis model recalibration in the large was accomplished by fitting a Cox
proportional hazards model with the linear predictor as the only parameter and estimating the
baseline survival at 30 days, setting the linear predictor equal to 0. The individual risks were recal-
culated by replacing the current baseline survival in the prognostic model with the updated value:
recalibrated linear predictor ¼ updated baseline survivaleðoriginal linear predictorÞ
Logistic recalibration. This method is used in cases where the coefficients of the original
model may have been over-fitted; it assumes similar relative effects of the predictors but allows
for a larger or smaller absolute effect of the predictors [26]. For the logistic regression models
this was achieved by fitting a model with the linear predictor of the original model as a single
predictor. The models were then updated by multiplying the linear predictor by the coefficient
and adding the estimated intercept; the individual risks were then recalculated:
recalibrated linear predictor ¼ updated interceptþ ðcoefficient x original linear predictorÞ
For the survival analysis model this was accomplished by fitting a Cox proportional hazards
model with the linear predictor as the only parameter and estimating the baseline survival at 30
days with the linear predictor equal to 0. The model was then updated by replacing the current
baseline survival value for the updated one and multiplying the linear predictor by the coeffi-
cient in the model; the individual risks were then recalculated:
recalibrated linear predictor ¼ updated baseline survivaleðcoefficient x original linear predictorÞ
Supporting Information
S1 Data. Data for the testing of the prognostic models.
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